Jeffrey J. Legos

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +7

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 658 citations · Full text

Medicine, Dermatology, Oncology +14

Caspase 3 activation is essential for neuroprotection in preconditioning

BethAnn McLaughlin, Karen A. Hartnett, Joseph A. Erhardt et al. · Proceedings of the National Academy of Sciences · 2003 · 271 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska et al. · The Lancet Oncology · 2015 · 262 citations

Medicine, Oncology, Pharmacology +11

SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia

Frank C. Barone, Elaine Irving, Aparajita Ray et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 216 citations

Medicine, Pharmacokinetics, Pharmacology +17